Absorption of the oral form is very limited—about 5% fasting, about 8% with food. It achieves a concentration in the central nervous system of about 50% of the plasma level. About 90% of plasma<unk>  is eliminated unchanged in the urine, with a half-life of 2–6 hours, depending on renal function (elimination takes over 24 hours in end-stage renal disease). Administration Acute infections are treated in two phases: *induction phase, 5 mg per kilogram intravenously every 12 hours for 14–21 days, the intravenous dose given as a 1-hour infusion *maintenance phase, 5 mg per kg intravenously every day Stable disease is treated with 1000 mg orally three times daily. Similar dosing is used to prevent disease in high-risk patients, such as those infected with human immunodeficiency virus (HIV) or those with organ transplants.<unk>  is also available in slow-release formulations for insertion into the vitreous humour of the eye, as treatment for CMV retinitis (associated with HIV infection). A topical ophthalmic gel preparation of<unk>  was recently approved for the treatment of acute herpes simplex keratitis.
Ganciclovir
Valganciclovir
Aciclovir
Penciclovir
Letermovir
Brincidofovir
Cidofovir
Lamivudine